Semaglutide: GLP-1 Receptor Agonist Research Overview
Semaglutide is a GLP-1 receptor agonist with a fatty acid modification enabling albumin binding and a plasma half-life of approximately one week. It has been extensively studied in metabolic disease models and has become a key research tool for understanding the GLP-1 axis.
Research Use Only. This article is for informational and research purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.
What Is Semaglutide?
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 plays a central role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways.
Semaglutide was engineered with two key structural modifications to extend its plasma half-life:
- Amino acid substitution at position 8 (alanine → α-aminoisobutyric acid) to resist DPP-4 degradation
- C18 fatty diacid chain attached via a linker to lysine at position 26, enabling reversible albumin binding
These modifications extend the plasma half-life to approximately 7 days in humans (vs. ~2 minutes for native GLP-1), enabling once-weekly dosing in clinical applications.
Molecular Profile
| Property | Value | |----------|-------| | Molecular Formula | C187H291N45O59 | | Molecular Weight | ~4,113.6 Da | | CAS Number | 910463-68-2 | | Receptor | GLP-1R (glucagon-like peptide-1 receptor) | | Half-life | ~7 days (human) |
Research Applications
Metabolic Disease Models Semaglutide is a primary research tool for studying type 2 diabetes and obesity models. Preclinical studies have examined its effects on insulin secretion kinetics, beta-cell preservation, hepatic glucose output, and adipose tissue metabolism.
Cardiovascular Research The SUSTAIN and PIONEER clinical trial programmes generated substantial data on cardiovascular endpoints. Preclinical research has examined mechanisms including reduced arterial inflammation, improved endothelial function, and direct cardiac effects via GLP-1R expression in cardiomyocytes.
Neurological and Appetite Research GLP-1 receptors are expressed in the hypothalamus, brainstem, and reward centres. Preclinical research has examined semaglutide's effects on appetite regulation, food reward behaviour, and potential neuroprotective effects in neurodegeneration models.
Non-Alcoholic Fatty Liver Disease (NAFLD) Multiple preclinical and clinical studies have examined GLP-1 receptor agonists in NAFLD/NASH models, with data suggesting reduced hepatic lipid accumulation and inflammation.
Comparison with Tirzepatide
| Feature | Semaglutide | Tirzepatide | |---------|-------------|-------------| | Receptor targets | GLP-1R only | GLP-1R + GIPR (dual agonist) | | Molecular weight | ~4,113 Da | ~4,813 Da | | Half-life | ~7 days | ~5 days | | Research application | GLP-1 axis studies | Dual incretin axis studies |
Research Quality Standards
Semaglutide's complex structure (fatty acid modification, multiple disulfide bonds) makes purity verification particularly important:
- HPLC purity ≥98% with chromatogram documentation
- Mass spectrometry confirmation (MW: ~4,113.6 Da)
- Endotoxin testing for in vivo studies
- Lyophilized format; store at -20°C
Research use only. Not for human administration.